N/A N=13 Evaluation of the Ketogenic Potential of Different Diet Supplements
Healthy Adults
Primary: Concentration of Total Plasma Ketones — -18.2; 23; 12.2; 68.5 µmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis
Healthy
Primary: Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet — 0.672; 4.83 µmol/100g/min
Phase 2 N=20 Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
Heart Failure With Preserved Ejection Fraction
Primary: Maximal Exercise Capacity (Peak VO2) Assessed by Cardiopulmonary Exercise Testing — 1.0; 1.0 L/min
Phase 1 N=20 Ketogenic Diet for Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants
N/A N=12 Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
Glioblastoma
Primary: Number of Participants With Ketosis — 9 Participants
N/A N=15 Ketone Supplementation in Cystic Fibrosis
Cystic Fibrosis
Primary: Pulmonary Function Testing — 1.9; 2.0 L/sec
N/A N=17 Ketogenic Diet in Advanced Cancer
Cancer
Primary: To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types. — 11 participants
Phase 1 N=20 Ketone Pharmacokinetic Study in HFrEF
Heart Failure With Reduced Ejection Fraction
Primary: Venous pH Measured Via Peripheral Blood — 7.30; 7.28 unitless
N/A N=50 Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Progression-free-survival — 20; 16 percentage of participants
N/A N=98 Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Phase 1 N=40 Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
N/A N=10 Ketone Production With Acute Caffeine Intake
Healthy Adults
Primary: Plasma Acetoacetate Concentrations — 26.06; 30.99; 32.10 µmol/L
N/A N=20 Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids
Healthy
Primary: Ketone Production — 217.71; 187.48 µmol/L
Phase 2 N=24 Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
Healthy Volunteers
Primary: Change in The Profile of Mood States - Bipolar Version (POMS - Bi) Composed-Anxious Subscale — -6.8; -11.9 score on a scale
N/A N=19 Exogenous Ketones in Type 2 Diabetes
Ketosis · Type 2 Diabetes
Primary: Plasma Glucose — 7.3; 7.2; 6.2; 6.6 mmol/L
N/A N=10 Effect of MCT Emulsification on Ketogenesis in Human Adults
Healthy
Primary: Plasma Ketone Concentration — 136.97; 177.43; 270.61; 249.3 µmol/L
N/A N=30 Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Metabolic Syndrome · Diabetes Mellitus, Type 2 · Pre Diabetes
Primary: Hemoglobin A1c — -.42; -0.37; 0.02 % of hemoglobin — p=0.001
N/A N=12 The Effect of Different Ketone Supplements on β-OHB and Blood Glucose in Healthy Individuals
Ketosis · Blood Glucose
Primary: Blood Beta-hydroxybutyrate — 217; 192; 176 area under the curve (mmol/L x 240 min)
N/A N=20 Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes
Prediabetic State
Primary: Plasma Ketone Concentrations — -52; 12; 493; 627 (µmol/h)/L
N/A N=53 Ketogenic Diet (KD) in Alcoholism
Alcoholism
Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067
N/A N=19 Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease
Parkinson Disease
Primary: Change in Duration of 80 Rpm Endurance Test — 26.31; 25.84; 15.62; 12.12 minutes
N/A N=16 Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More
Ketosis
Primary: Change in Venous Plasma Beta-hydroxybutyrate (BHB) From Baseline to Peak During Acute Ketosis Exposure — 3.5; 0.04 mmol/l
Phase 1 N=21 Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Empaglifozin · Physiological Effects of Drugs · Hypoglycemic Agents
Primary: Change in Serum β-hydroxybutyrate (BHB) — 40.717 µM — p=<0.001
Phase 2 N=10 Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
GLUT1DS1
Primary: Change in Ketosis (Beta-hydroxybutyrate Levels) — 3.82 mM
N/A N=10 Comparing the Ketogenic Effect of Coconut Oil and Different MCTs
Healthy Adults
Primary: Plasma Ketone Concentrations — 69; 294; 109; 363 µmol/L
N/A N=14 An Study Investigating Nic's Keto Diet on Cardiovascular Health in Healthy Adults With Mildly Elevated LDL Levels
Ketogenic Dieting · Healthy
Primary: Changes to Body Fat Percentage as Assessed by DEXA Scan From Baseline to Day 70 Following Nic's Keto Diet — -2.25 percentage of body fat
Phase 1 N=16 Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)
Parkinson's Disease
Primary: Feasibiilty of Ketogenic Diet - Retention (Co-primary Endpoint) — 15 Participants
N/A N=54 Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older
Metabolic Syndrome · Normal Cognition
Primary: Change in β-hydroxybutyrate in the Posteromedial Cortex Measured by ¹H-MRS (PRESS) — 1.847; 0.922; 1.265; 1.172 Ratio
N/A N=17 Effects of Diet on Brain Processing
HIV · Neurocognitive Impairment
Primary: Neurocognition: Mean Score of Hopkins Verbal Learning Test (Total) at Baseline — 29.4; 31.1 score on a scale
N/A N=160 A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
Diabetes Mellitus · Obesity
Primary: Change From Baseline in Body Weight at 48 Weeks — -9.5; -8.5 percentage of weight loss